Madrigal Pharma

MDGL

437.7400.81% ( +3.500 )

Closed: Oct 26, 16:00:01 (EDT)

Q2 FY2026 Earnings

Financial report interval: 2026.03.30 - 2026.06.30

Overview: Madrigal Pharma(MDGL) the Revenue is 364.25 M (+71.17%), Beat estimate;the EBIT is -56.31 M (-19.29%), Beat estimate;the EPS is -1.99 (-4.74%), Beat estimate.

Actual

YoY

Estimate

YoY

Vs estimate

YoY

RevenueExceed expectations

0.36B71.17%

0.35B65.96%

+0.01B5.21%

EBITExceed expectations

-0.06B19.29%

-0.08B65.58%

+0.02B46.29%

EPSExceed expectations

-1.994.74%

-2.640438.97%

+0.650434.23%

Upcoming earnings report - Q3 FY2026

Available dateNov 3, 2026

Estimate Revenue$405.12 M

Estimate EBIT-$27.37 M

Estimate EPS-$0.873

Revenue

ActualEstimateUnit: USD

Quarterly

EBIT

ActualEstimateUnit: USD

Quarterly

Net income

ActualEstimateUnit: USD

Quarterly

EPS

ActualEstimateUnit: USD

Quarterly